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Caprine arthritis encephalitis virus transcription is under the control of the viral promoter within the long terminal repeat. Previous studies with
the closely related maedi visna lentivirus have indicated that viral transcription is dependent upon the AP-1 transcription factor. Other studies have
indicated a potential role for the cytokines TNFα and GM-CSF in CAEV pathogenesis by increasing viral loads in infected tissues. The
hypotheses that AP-1 transcription factors are necessary for transcriptional activation of the CAEV promoter and that CAEV transcriptional
activation results from treatment with the cytokines GM-CSF and TNFα were tested with a stably transduced U937 cell line. Here, we found that
TNFα and GM-CSF activated CAEV transcription in U937 cells. However, this activation effect was not blocked by SP600125, an inhibitor of
Jun N-terminal kinase. SP600125 effectively prevented Jun phosphorylation in cells subsequently treated with cytokines. The cytokines TNFα
and GM-CSF therefore activate CAEV transcription, and this effect occurs independently of AP-1. A set of progressive deletion mutants was
utilized to show that TNFα-induced expression depends on an element or elements within the U3 70-bp repeat.
© 2006 Elsevier Inc. All rights reserved.Keywords: CAEV; TNFα; GM-CSF; AP-1; TranscriptionIntroduction
Caprine arthritis encephalitis virus (CAEV) and maedi visna
virus (MVV) are closely related lentiviruses that infect goats
and sheep, respectively. These two small ruminant lentiviruses
(SRLV) share many key features including similarities in
genome structure, disease pathogenesis and host cell tropism.
CAEV is a monocyte–macrophage tropic lentivirus that causes
a nonsuppurative inflammatory disease complex in naturally
and experimentally infected goats (Cheevers and McGuire,
1988; Crawford et al., 1980; Cush and Lipsky, 1991; von
Bodungen et al., 1998; Zvaifler and Firestein, 1994). Virus
replication within the monocyte–macrophage results in lesions
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doi:10.1016/j.virol.2006.04.017joints (caprine arthritis, CA), central nervous system, lungs and
mammary gland (Kennedy-Stoskopf et al., 1987). CA, the most
clinically relevant consequence of CAEV infection, is a chronic
progressive synovitis resulting in accumulation of synovial
fluid, periarticular swelling, soft tissue mineralization and
erosion of articular surfaces (Wilkerson et al., 1995).
The precise mechanism(s) whereby CAEV infection results
in tissue pathology remains controversial. However, several in
vivo and in vitro experiments indicate that the cytokines tumor
necrosis factor-alpha (TNFα) and granulocyte–macrophage
colony stimulating factor (GM-CSF) play a role in CA lesion
development. In rheumatoid arthritis, a related chronic
inflammatory disease of humans, TNFα is considered a key
regulatory cytokine (Lechner et al., 1996), and both TNFα and
GM-CSF mRNA are elevated within the joint synovium
(Firestein et al., 1990). CAEV-infected goats have elevated
serum TNFα levels compared to uninfected control goats
(Mdurvwa et al., 1994). Macrophages producing abundant
TNFα mRNA have been demonstrated in synovial tissue of
goats with CA lesions and correlate with lesion severity
(Lechner et al., 1996, 1997b). TNFα mRNA has been detected
Fig. 1. PMA activates CAEV transcription in U937 cells. Real-time reverse
transcriptase polymerase chain reaction (RT-PCR) time course analysis for Gag
mRNA of U937CAEV cells exposed to 10 μM PMA at varying time points.
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infection (Lechner et al., 1997b). Macrophages infected with
CAEV in vitro and stimulated with LPS express more GM-CSF
mRNA than mock infected cells (Lechner et al., 1997a). In
MVV infected sheep, GM-CSF mRNA expression in alveolar
macrophages correlates with the presence of pulmonary lesions
(Woodall et al., 1997; Zhang et al., 2002). These observations,
coupled with the observation that CAE viral loads correlate with
lesion severity (Cheevers et al., 1991, 1988), suggest that the
cytokines TNFα and GM-CSF may augment CA lesion severity
by increasing viral loads within the infected tissues.
AP-1 is a collective term referring to dimeric transcription
activators composed of homodimers or heterodimers of Jun, Fos
or closely related factors (Krauss, 2003). AP-1 has been
proposed as a key regulator of both MVV (Gabuzda et al., 1989;
Hess et al., 1989) and CAEV transcription (Kalinski et al.,
1994). The SRLV promoters are located within the U3 region of
the viral long terminal repeat (LTR). Within the U3 region, the
MVV promoter has a consensus AP-1 site (TGAG/CTCA)
proximal to the TATA box which appears to be critical for
efficient transcription (Gdovin and Clements, 1992; Hess et al.,
1989; Neuveut et al., 1993) and is required for phorbol ester-
inducible gene expression (Gabuzda et al., 1989). In addition to
the consensus site, multiple degenerate sites are present within
the MVV promoter. It has been proposed that the degenerate
AP-1 sites discriminate between AP-1 complexes of different
compositions (Sutton et al., 1997). In contrast to MVV, the
CAEV CO (CAEV Cork isolate) promoter has a near consensus
AP-1 sequence (TGAGACA) near the 5′ end of the U3 region
and four degenerate copies of the AP-1 consensus sequence of
unknown relevance. AP-1 binding activity has been found to be
decreased in CAEV-infected macrophages leading to the
speculation that in cells replicating CAEV, free AP-1 becomes
sequestered by viral AP-1-like binding sites resulting in reduced
levels of nuclear AP-1 (Lechner et al., 1997a).
The cytokines TNFα and GM-CSF activate AP-1-mediated
transcription through mechanisms involving mitogen-activated
protein (MAP) kinase signaling cascades (Karin et al., 1997;
Shaulian and Karin, 2002). Agents known to trigger AP-1
activity are also potent inducers of monocyte differentiation
and macrophage activation (Sutton et al., 1997). CAEV viral
antigen expression is repressed in monocytes (Gendelman et
al., 1986; Hess et al., 1986), while differentiation of
monocytes into macrophages results in viral RNA expression
(Gabuzda et al., 1989; Shih et al., 1992) indicating that cellular
factors such as AP-1 are involved in the regulation of viral
gene expression (Neuveut et al., 1993). These observations
suggest that TNFα and GM-CSF-induced activation of AP-1
factors may be transcriptionally linked to both macrophage
differentiation and CAEV transcription. Clarifying this con-
nection may be important, since activation of CAEV
transcription augments CA lesion severity by increasing viral
loads within the infected tissue. Here, we tested two
hypotheses: (i) whether CAEV transcriptional activation
results from exposure to the cytokines GM-CSF or TNFα,
and (ii) whether AP-1 factors are necessary for transcriptional
activation of the CAEV promoter.Results
TNFα and GM-CSF activate CAEV expression in
U937CAEV cells
To test the hypothesis that TNFα and GM-CSF activate the
CAEV promoter, U937CAEV and GSMCAEV cells were exposed
to various concentrations of recombinant human cytokines for
varying lengths of time. Exposure to a phorbol ester (PMA) was
used as a positive control. Phorbol esters have been used in
many studies as activators of SRLV promoters (Gabuzda et al.,
1989; Shih et al., 1992; Tong-Starksen et al., 1996). U937CAEV
cells were exposed to PMA for varying lengths of time, and the
Gag mRNA copy number was determined by real-time RT-
PCR. U937CAEV cells exposed to 10 μM PMA for 0 to 48 h had
peak Gag mRNA expression at 24 h, approximately 10-fold
activation over the background expression at time zero
(P < 0.05, Fig. 1). This experiment was independently repeated
three times with similar results. The data presented in Fig. 1
indicate that exposure of U937CAEV cells to PMA results in
statistically significant increases in Gag mRNA expression.
At 4 h, U937CAEV cells exposed to the human cytokines
TNFα (10 ng/ml) or GM-CSF (50 ng/ml) had approximately
3.2-fold increased CAEV Gag mRNA expression (P < 0.05)
over control samples at time zero (Figs. 2a and c). U937CAEV
cells exposed to 0–10 ng TNFα/ml or 0–50 ng GM-CSF/ml for
2 h had a dose-response activation of CAEV Gag mRNA
expression with a maximal activation at 10 ng TNF α/ml or 5 ng
GM-CSF/ml, respectively (P < 0.05; Figs. 2b and d). These
experiments were repeated a minimum of three times for each
cytokine with similar results. Exposure of U937CAEV cells to
both GM-CSF and TNFα for 4 h did not result in additional
promoter activation (i.e., a synergistic effect was not detected,
data not shown). Goat-derived GSMCAEV cells exposed to the
human cytokines TNFα (10 ng/ml) or GM-CSF (50 ng/ml) for 4
h had a statistically significant 1.9- or 1.4-fold increase in
CAEV Gag expression, respectively (Fig. 3). This experiment
was performed two times with similar results. In all of the
Fig. 2. TNFα and GM-CSF activate CAEV transcription in U937 cells. (a) Real-time RT-PCR time course analysis for Gag mRNA of U937CAEV cells exposed to an
initial concentration of 10 ng TNFα/ml media. (b) Real-time RT-PCR dose-response analysis for Gag mRNA of U937CAEV cells exposed to 0–10 ng TNFα/ml for 2 h.
(c) Real-time RT-PCR time course analysis for Gag mRNA of U937CAEV cells exposed to an initial concentration of 50 ng GM-CSF/ml. (d) Real-time RT-PCR dose-
response analysis for Gag mRNA of U937CAEV cells exposed to 0–50 ng GM-CSF/ml for 2 h. The RT− lane corresponds to untreated control sample lacking reverse
transcriptase.
Fig. 3. TNFα and GM-CSF activate CAEV transcription in GSM cells. Real-
time RT-PCR analysis for Gag mRNA of GSMCAEV cells exposed to media
alone (control), an initial concentration of 10 ng TNFα/ml media or an initial
concentration of 50 ng GM-CSF/ml for 4 h. The RT− lane corresponds to
untreated control sample lacking reverse transcriptase.
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(RT−) did not yield Gag amplification products indicating that
the DNase treatment step was effective.
Tumor necrosis factor alpha and GM-CSF therefore activate
the CAEV promoter, both in human-derived U937 cells and in
goat-derived GSM cells. In regard to the expression kinetics,
U937CAEV cells treated with TNFα or GM-CSF had
statistically significant increases in CAEV Gag mRNA
expression with a maximal effect at 4 h. TNFα treatment
produced a transient increase in Gag mRNA expression which
decayed to background levels by 24 h. In contrast, cells treated
with GM-CSF had a persistent increase in Gag expression at
24 h.
The inhibitor SP600125 does not reverse PMA, TNFα and
GM-CSF induced promoter activation
We tested the hypothesis that PMA and cytokine-induced
CAEV promoter activation is mediated through AP-1 factors by
SP600125-induced inhibition of Jun N-terminal kinase activity
(JNK). Activation of JNK results in phosphorylation of Jun at
Ser 63 and Ser 73 (Krauss, 2003). Phosphorylation of Jun
191B.G. Murphy et al. / Virology 352 (2006) 188–199enhances its transcriptional activity (Shaulian and Karin, 2002;
Smeal et al., 1994) and increases the protein's stability (Karin et
al., 1997; Kracht and Saklatvala, 2002). Previous experiments
with SP600125 have demonstrated a greater than 300-fold
specificity of JNK inhibition relative to other MAP kinases
(Bennett et al., 2001).
U937CAEV cells treated with 40 μM SP600125 for 2 h prior
to exposure to 10 μM PMA for 24 h demonstrated no decrease
in Gag mRNA copy number relative to PMA-treated cells alone
(Fig. 4a). Exposure of U937CAEV cells to 40 μM SP600125 for
2 h prior to a 4-h exposure to 10 ng TNFα/ml or 50 ng GM-
CSF/ml (Figs. 4b and c, respectively) did not block cytokine-
induced U3 promoter activation.
Surprisingly, a statistically significant increase in Gag
mRNA expression was identified in cells treated with both
cytokine and SP600125 (*) when compared to cells treated with
cytokine alone. These experiments were repeated four or more
times with each agent with similar results. U937CAEV cells
exposed to 30 or 40 μM SP600125 for 6 h had a statistically
significant increase in expression of Gag mRNA (*) relative to
untreated control cells (Fig. 4d).Fig. 4. The JNK inhibitor SP600125 does not inhibit PMA and cytokine-induced CAE
analysis for Gag mRNA of U937CAEV cells treated with 40 μM SP600125 2 h prior t
mRNA of U937CAEV cells treated with 40 μM SP600125 for 2 h prior to exposure to
were harvested after a total incubation time of 6 h. (d) Real-time RT-PCR analysis fo
lanes correspond to untreated control sample lacking reverse transcriptase.U937CAEV cells treated with SP600125 and PMA had
approximately the same Gag mRNA expression relative to
PMA-treated cells alone (10-fold over the untreated control
cells, Fig. 4a). Cells treated with both a cytokine and SP600125
had 2- to 4-fold more Gag expression relative to cytokine-
treated cells alone (Figs. 4b and c). CAEV promoter activation
may be maximized (saturated) in PMA-treated cells, preventing
further activation by SP600125 treatment. In cytokine-treated
cells, promoter activation does not appear to be saturated. This
observation suggested that PMA and cytokines may activate the
CAEV promoter by different molecular mechanisms, which is
consistent with the different time course kinetics of activation
(Figs. 1 and 2).
To confirm the effectiveness of JNK inhibition by
SP600125 in U937CAEV cells, a Western blot was performed
with lysates from cytokine- or PMA-treated cells. U937CAEV
cells were treated with or without 40 μM SP600125 for 2
h then exposed to either TNFα (10 ng/ml), GM-CSF (50 ng/
ml) or 10 μM PMA and incubated an additional 4 h prior to
the lysate harvest. Equivalent amounts of protein were loaded
per lane onto two gels run in parallel. The subsequent blotsV promoter activation but activates the CAEV promoter. (a) Real-time RT-PCR
o a 24-h exposure to 10 μM PMA. (b and c) Real-time RT-PCR analysis for Gag
either 10 ng TNFα/ml (b) or 50 ng of GM-CSF/ml (c) for 4 h. The treated cells
r Gag mRNA of U937CAEV cells exposed to 0–40 μM SP600125 for 6 h. RT−
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phosphorylated c-Jun (Ser 73) or a monoclonal antibody
against c-Jun. Bands corresponding to phosphorylated c-Jun
were present in the TNFα, GM-CSF and PMA-treated samples
but were either absent or greatly attenuated in samples
previously treated with SP600125 (Fig. 5a). The phosphory-
lated c-Jun antibody also recognizes phosphorylation of JunD
(ser 100); bands corresponding to phosphorylated JunD were
not detected for any treatment. The control blot treated with
the c-Jun monoclonal antibody (Fig. 5b) confirms that a
similar amount of c-Jun was expressed for each treatment
condition. Cells treated with cytokine or PMA alone have an
additional band (between 40 and 50 kDa) corresponding to the
phosphorylated form of c-Jun; this band is absent in the
SP600125-treated lanes. This experiment was repeated twice
with similar results. A dose-response experiment was
performed with SP600125 in order to titrate the effect of the
inhibitor (Fig. 5c). U937CAEV cells were treated with 0–40 μM
SP600125, incubated for 2 h and exposed to 0 or 10 ng TNFα/
ml for 4 h prior to lysate harvest. The Western blot was
performed as described previously with anti-phosphorylated c-Fig. 5. The JNK inhibitor SP600125 blocks cytokine and PMA-induced phosphoryl
analyses of U937CAEV cell lysates (50 μg protein/lane) with or without exposure to 40
ml, 10 μM PMA or no treatment (control) for 4 h. The primary antibodies were anti-p
lysates (50 μg protein/lane) exposed to 0, 5, 10 or 40 μM SP600125 for 2 h prior to
loaded per lane. (d) Human matrix metalloproteinase 12 RT-PCR analysis of RNA
SP600125 (lane 2) for 19 h. This experiment was repeated three times with similarJun (Ser 73) as the primary antibody. An inhibitory dose-
response effect was evident with increasing concentrations of
SP600125. In previously published experiments, 10 μM
SP600125 effectively inhibits 90 to 100% of Jun N-terminal
kinase activity (Bennett et al., 2001). To demonstrate that
SP600125 treatment decreases AP-1-mediated transcription,
we utilized the AP-1-dependent gene metalloproteinase (Wu et
al., 2001). Treatment of U937CAEV cells with 40 μM SP60015
for 19 h blocked mRNA expression of metalloproteinase 2.3-
fold (Fig. 5d). This experiment was repeated three times with
similar results.
The results indicated that 40 μM SP600125 effectively
inhibited JNK activity, as measured by blockade of c-Jun
phosphorylation and inhibition of mRNA transcription of the
AP-1 dependent gene metalloproteinase. 40 μM SP600125
effectively inhibited phosphorylation of c-Jun in cells subse-
quently treated with cytokines or PMA. Collectively, these
results indicated that phosphorylated Jun protein (and therefore,
AP-1 transcription factor) is not required for activation of the
CAEV promoter by PMA, GM-CSF or TNFα. Activation of the
CAEV promoter therefore occurs independently of AP-1.ation of Jun and inhibits metalloproteinase transcription. (a and b) Western blot
μMSP600125 for 2 h prior to incubation with 10 ng TNFα/ml, 50 ng GM-CSF/
hosphorylated Jun-73 (a) or c Jun (b). (c) Western blot analysis of U937CAEV cell
exposure to 10 ng TNFα/ml or no treatment for 4 h. 50 μg of total protein was
extracted from U937CAEV cells exposed to control media (lane 1) or 40 μM
results.
Fig. 6. Flow cytometry analysis of U937CAEV cells treated with SP600125. U937CAEV cells were incubated with or without 40 μM SP600125 for 5 or 24 h: (a) 5 h, no
treatment; (b) 5 h with SP600125; (c) 24 h, no treatment; (d) 24 h with SP600125. The cells were fixed, stained with propidium iodide and analyzed for DNA content
via FlowJo software.
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In order to explain the anomalous SP600125-induced
activation of the CAEV promoter identified in Fig. 4, weFig. 7. Maps of the CAEV-CO U3 region and derived deletion mutants. The transcript
bp repeats are denoted by large open boxes. Portions of the U3 region deleted in each
9069, 9007–9037 and 8995–9014, for U937CAEΔ1, U937CAEΔ2, U937CAEΔ3, U937determined the DNA content of U937CAEV cells treated with or
without SP600125. In HIV-infected cells, G2 arrest has been
shown to be associated with an enhancement of transcriptional
activity (Bouzar et al., 2003; Goh et al., 1998; Mueller andion factor binding motifs are represented as labeled black boxes, and the two 70-
mutant are as follows: nucleotides 8856–9069, 8923–9069, 8994–9069, 9037–
CAEΔ4, U937CAEΔAP4 and U937CAEΔAML, respectively.
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activity of the SP600125-treated cells was the result of G2/M
block. Cells blocked in the G2 phase of the cell cycle
accumulate a 4n complement of genomic DNA, which can be
quantified by flow cytometry.
U937CAEV cells were incubated with or without 40 μM
SP600125 for 0 to 24 h. Both treated and untreated cells were
fixed and stained at 0, 2, 5, 7 and 24 h, as described in the
Materials and methods. U937CAEV cells exposed to SP600125
for 5 and 24 h (Figs. 6b and d) had an increase in the 4n DNA
content relative to untreated cells (Figs. 6a and c). The G2/G1
ratio increases from 0.55 at time zero to 0.82, 1.6, 2.5 and 9.7 at
2, 5, 7 and 24 h, respectively. This experiment was performed
twice with similar results. Cells treated with 40 μM SP600125
for 2 h and subsequently exposed to cytokines or PMA for 4 h
had the same G2/G1 ratio as cells exposed to SP600125 alone
for 6 h (data not shown).Fig. 8. The U3 70-bp repeat is necessary and sufficient for TNFα-induced promo
U937CAEΔ2, U937CAEΔ3, U937CAEΔ4, U937CAEΔAP4, U937CAEΔAML, U937CAEVand
and Rrev primer set. (b) Real-time RT-PCR results for Gag mRNA of U937CAEV, U
without (black bars) exposure to 10 ng TNFα/ml for 4 h. The difference between
statistically significant (*). The RT− lane corresponds to untreated control sample
U937CAEV, U937CAEΔAP4 and U937CAEAML cells with (grey bars) or without (black b
control sample lacking reverse transcriptase. (d) Relative basal and TNFα-induced
figures, 1× basal promoter function was defined as the Gag copy number for untreaThe results show that the JNK inhibitor SP600125
effectively blocks U937CAEV cells in the G2 phase of the cell
cycle, resulting in an increase in the 4n DNA content of the
treated cells.
The U3 70-bp repeat is required for TNFα-induced promoter
activation
Since activation of the CAEV promoter occurs indepen-
dently of AP-1, a set of six U3 deletion mutants were
constructed (Fig. 7) in order to define the locus of TNFα-
induced transcriptional activation. For each mutant, the U3
region was sequenced and determined to match the predicted
sequence. Stably integrated, U937-based cell lines were
generated from each CAEV-mutant construct as described in
the Materials and methods. A PCR reaction was performed
utilizing genomic DNA from each cell line with the Revfor andter activation. (a) PCR products of genomic DNA isolated from U937CAEΔ1,
parent U937 cells (lanes 1–8, respectively). PCR was performed with the Revfor
937CAEΔ1, U937CAEΔ2, U937CAEΔ3 and U937CAEΔ4 cells with (grey bars) or
TNFα exposed and unexposed Gag mRNA copy number for U937CAEΔ2 is
lacking reverse transcriptase. (c) Real-time RT-PCR results for Gag mRNA of
ars) exposure to 10 ng TNFα/ml for 4 h. The RT− lane corresponds to untreated
promoter function for the data pictorially presented in panels b and c. For both
ted U937CAEV cells.
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product size (Fig. 8a, lanes 1–6). To confirm the presence of an
unmodified U3 promoter region within the U937CAEV cell line,
genomic DNAwas isolated, and a PCR reaction was performed
utilizing the same primer set (Fig. 8a, lane 7). This PCR product
was sequenced and determined to be identical to the wild-type
CAEV-CO U3 sequence. No product was detected when the
same PCR reaction was performed with genomic DNA isolated
from parent U937 cells (negative control, Fig. 8a, lane 8).
The U3 deletion mutant cell lines were treated with or
without TNFα (10 ng/ml) for 4 h prior to RNA harvest. The Gag
mRNA copy number was determined by real-time RT-PCR.
When corrected for equal numbers of integrating constructs,
U937CAEΔ1 cells had a 26-fold attenuation of the basal Gag
mRNA expression (Fig. 8b). Importantly, U937CAEΔ1 had no
increase in Gag mRNA expression in response to TNFα
treatment. However, U937CAEΔ2 cells, with a single copy of the
U3 70-bp repeat, had a 0.5-fold basal Gag mRNA expression
relative to the wild-type U937CAEV cells and a statistically
significant 1.6-fold activation in response to TNFα exposure
(Figs. 8b and d). The deletion mutants U937CAEΔ3 and
U937CAEΔ4 had a similar basal expression level and a
progressively stronger response to TNFα exposure (3.9- and
5.2-fold, respectively). Two other deletion mutants, U937-
CAEΔAP4 and U937CAEΔAML, had a 4.5- and 7.5-fold activation
in response to TNFα, and a 1- and 0.5-fold basal expression,
respectively (Figs. 8c and d). Samples without reverse
transcriptase (RT-) did not yield gag amplification products.
These experiments were repeated once with similar results.
In U937CAEΔ1 cells, the basal promoter function was
severely attenuated, and the TNFα-induced promoter activation
was abrogated. However, in U937CAEΔ2 cells, the basal and
TNFα-induced promoter functions were attenuated but present.
These results suggest that TNFα-induced expression is
dependent upon an element or elements within the U3 70-bp
repeat. In comparison to the 1.6-fold activation demonstrated
with U937CAEΔ2 cells, the cell line U937CAEΔ3 has two copies
of the 70-bp repeat and a 3.9-fold response to TNFα treatment.
This suggests a dosage effect with the additional repeat element.
These data also indicate that basal U3 promoter function is
dependent on multiple loci within the U3 region including: the
70-bp repeat, AML and nucleotides 9037–9068 (the region
deleted in U937CAEVΔ4 cells). Note that the 5′ near consensus
AP-1 motif is present in all of the deletion mutants (Fig. 7)
supporting the concept that AP-1 is not sufficient to confer
TNFα-induced responsiveness in the CAEV promoter.
These promoter deletion results are consistent with the
concept that cytokine-induced activation is not the result of
random integration of the construct adjacent to a cytokine-
responsive cellular promoter. In addition, these results indicate
that the cytokine-induced increase in Gag mRNA is a
transcriptional effect and not a result of transcript stabilization.
Discussion
Previous investigations into the transcriptional regulation of
SRLV have utilized transient transfections with LTR promoter–reporter gene constructs. The in vivo biological relevance of
these experiments has been limited by the episomal location of
the viral promoter, the lack of viral protein expression and
confounded by variation in transfection efficiency among
experimental groups. For these reasons, CAEV constructs
were stably integrated into the U937 cell genome. The human-
derived U937 cell line was chosen as it facilitates the utilization
of a greater variety of research reagents. This cell line allows the
exploration of viral promoter regulation in the more biologically
relevant context of an integrated provirus.
Exposure of U937CAEV cells to PMA, GM-CSF or TNFα
resulted in 10-, 3.2- and 3.2-fold CAEV promoter activation,
respectively. Goat-derived GSMCAEV cells exposed to recom-
binant human TNFα and GM-CSF had a statistically
significant but attenuated activation. Recent findings indicate
that GSM cells are not of the monocyte–macrophage lineage
(B. Davis, personal communication). As CAEV is a mono-
cyte–macrophage tropic virus, it is not surprising that viral
promoter activation in GSM cells is attenuated relative to the
monocyte–macrophage U937 cell line. In previously published
experiments, TNFα did not activate the CAEV promoter in
U937 cells above baseline levels (Tong-Starksen et al., 1996).
However, these experiments relied on a transient transfection
system with a LTR-CAT reporter construct and were
conducted with a 24-h cytokine exposure time. The data
presented here clearly indicate a maximal TNFα induction
effect at 4 h which degrades to background levels by 24 h.
This is the first report describing TNFα and GM-CSF-induced
transcriptional activation of an integrated CAEV construct.
These results are consistent with the hypothesis that CAEV
transcriptional activation results from exposure to the
cytokines GM-CSF or TNFα. As it has previously been
demonstrated that increased CAE viral loads are associated
with increased lesion severity (Cheevers et al., 1991, 1988),
the cytokines TNFα and GM-CSF may play a role in CA
pathogenesis by activation of the CAE viral promoter leading
to increased virus production.
In this study, we also tested the hypothesis that AP-1
transcription factors are necessary for transcriptional activa-
tion of the CAEV promoter. To test this hypothesis, we
utilized the JNK inhibitor SP600125. Western blot assays
indicated that SP600125 effectively blocked phosphorylation
of c-Jun and prevented TNFα, GM-CSF and PMA-induced
phosphorylation of c-Jun. In addition, SP600125 attenuated
transcription of the AP-1-dependent metalloproteinase gene.
Treatment with SP600125, however, failed to block PMA
and cytokine-induced activation of the viral promoter
indicating that AP-1 transcription factors are not required
for activation of the CAEV promoter by PMA, GM-CSF or
TNFα. In support of this conclusion, the U937CAEVΔ1
mutant cell line has a near-consensus copy of the AP-1 motif
yet the basal promoter function was severely attenuated, and
the TNFα-induced promoter function was abrogated. Inter-
estingly, SP600125 was found to activate the CAEV
promoter. Experiments described here indicate that
SP600125 effectively blocks the U937 cells in G2 phase
of the cell cycle, leading to an increased G2/G1 ratio and 4n
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an enhancement of transcriptional activity in HIV-infected
cells. The CAEV tat gene product is currently thought to be
functionally analogous to the lentiviral accessory protein Vpr
(Villet et al., 2003). One of the functions of Vpr is to arrest
virally infected cells in G2 phase (Bartz et al., 1996; Jowett et
al., 1995). SP600125 treatment may complement the tat-
deleted genotype of the U937CAEV cells resulting in cell cycle
arrest and increased transcriptional activity of the CAEV
promoter.
Since AP-1 is apparently not required for TNFα or GM-
CSF-induced activation of the CAEV promoter, transcription
experiments were performed to localize the required promoter
regions. A set of progressive U3 deletion mutants indicate that
the 70-bp repeat is required for TNFα-induced promoter
activation. A consensus, gamma-activated site (GAS) is present
within the 70-bp repeat and has been previously shown to be
responsive to the cytokine interferon gamma (IFN gamma)
(Tong-Starksen et al., 1996). The CAEV GAS element
resembles the well-conserved GAS sequence of cellular genes
and a minimal promoter composed of the GAS element is
sufficient to confer responsiveness to IFN gamma (Sepp and
Tong-Starksen, 1997). IFN gamma-induced CAEV promoter
activation has been shown to be mediated through the
transcriptional factor STAT1 (Sepp and Tong-Starksen, 1997).
TNFα (Guo et al., 1998) and GM-CSF (Jackson et al., 2004)
initiate signaling cascades resulting in STAT1 activation.
Interestingly, STAT1 has also been shown to play a pivotal
role in the differentiation of monocytes into macrophages
(Coccia et al., 1999). It is possible that TNFα and GM-CSF-
induced CAEV promoter activation is mediated through STAT1
binding of the U3 GAS site. Experiments are ongoing to test this
hypothesis.
Materials and methods
Plasmids
The plasmid CAEVpac11 was generated from the
previously described pCAEVneo11 (Hotzel and Cheevers,
2001). This plasmid has the CAEV-CO strain (Cork and
Narayan, 1980) proviral sequence with a 1330-bp deletion in
env and an SV40-pac (pac: puromycin acetyltransferase)
cassette replacing the tat gene. The plasmids CAEΔ1,
CAEΔ2, CAEΔ3, CAEΔ4, CAEΔAP4 and CAEΔAML
have deletions between nucleotides 8856–9069, 8923–9069,
8994–9069, 9037–9069, 9007–9037 and 8995–9014, respec-
tively. For each plasmid, two unique primers were designed
flanking the deleted region: 5′ U3rev/TATA-bglfor, U3rev/
TATA-bglfor, U3rev/TATA-bglfor, AP4rev/TATAbglfor, AMLrev/
U3for and U3rev/AP4for for plasmids CAEΔ1, CAEΔ2,
CAEΔ3, CAEΔ4, CAEΔAP4 and CAEΔAML, respectively.
Each primer was designed with a unique BglII restriction site
at the 5′ end. For each primer set above, the reverse primer
was utilized in a PCR reaction with the Revfor primer, and the
forward primer was utilized with Rrev to generate two PCR
products. The unique BglII ends allow reconstruction of theU3 region with the appropriate deletion. All cloning steps
involving PCR were checked by sequencing to confirm the
absence of PCR-induced sequence errors. The plasmid
pMEVSV-G, expressing the vesicular stomatitis virus (VSV)
G glycoprotein (utilized for packaging), was obtained from
Richard Sutton. All plasmids were propagated in Escherichia
coli JM109.
Cells and tissue culture media
The U937 cells were obtained from the American Type
Culture Collection (ATCC, Manassas, VA). The U937 cell line
is frequently used for in vitro SRLV studies (Sepp and Tong-
Starksen, 1997; Shih et al., 1992; Tong-Starksen et al., 1996).
U937 cells were maintained at 37 °C in 5% CO2 in RPMI 1640
media with L-glutamine (Gibco BRL, Grand Island, NY)
supplemented with 12% fetal calf serum (FCS), 100 U
penicillin/l, 100 μg streptomycin/l and 2-mercaptoethanol
(2 μl/500 ml media). 293T cells (utilized for generating
pseudotyped virus) were grown in Dulbecco's modified Eagle
medium (DMEM, Gibco BRL, Grand Island NY) supplemented
with 10% FCS, 100 U penicillin/l, 100 μg streptomycin/liter
and 2 mM L-glutamine. Goat synovial membrane (GSM) cells
were derived and maintained as previously described (Klevjer-
Anderson and Cheevers, 1981).
Derivation of cell lines
U937 cells, along with the plasmids CAEVpac11, CAEΔ1,
CAEΔ2, CAEΔ3, CAEΔ4, CAEΔAP4 and CAEΔAML were
utilized to generate the cell lines: U937CAEV, U937CAEΔ1,
U937CAEΔ2, U937CAEΔ3, U937CAEΔ4, U937CAEΔAP4 and
U937CAEΔAML, respectively. Pseudotyped virus was generated
in 293T cells; the cells were plated in 60-mm plates and
allowed to adhere overnight. On day 2, the cells were
cotransfected with 8 μg of one of the CAEV plasmids and
4 μg pMEVSV-G using a commercially available calcium-
phosphate transfection kit (Profection Mammalian Transfection
Systems, Promega). Culture medium was replaced 24 h after
transfection (day 3). Pseudotyped virus was harvested on day 4
from media spun at 3000 rpm at 4 °C for 20 min to remove
cellular debris. U937 cells were seeded in a 25-cm2 tissue
culture flask with 2 ml RPMI 10%-FCS and 2 ml of
pseudotyped virus. Control U937 cells were placed in 4 ml of
RPMI 10%-FCS without virus. The flasks were swirled every
10 min for 90 min, and the volume was subsequently adjusted
to 8 ml RPMI 10%-FCS per flask. Two days later (day 6), the
cells were placed in 75-cm2 flasks, and the media were replaced
with RPMI 10%-FCS containing 0.5 μg puromycin/ml. The
media were changed daily and the cells were kept in puromycin
selection for 14 days until 100% of the control cells were dead.
Integration of the CAEV constructs into the U937 cell genome
was confirmed by RT-PCR with total RNA utilizing Gag and
U3 primers and PCR with genomic DNA and U3 primers (as
described below). GSMCAEV cells were derived from GSM
cells and the pCAEVpac11 plasmid in the same manner as for
U937CAEV cells.
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The recombinant human cytokines TNFα and GM-CSF
(R&D Systems, Inc., Minneapolis, MN) were solubilized in
PBS with 0.1% bovine serum albumin at stock concentrations
of 10 μg/ml and 5 μg/ml, respectively. The cytokines were filter
sterilized and split into 100 μl aliquots. Phorbol myristate
acetate (PMA, Sigma Aldrich) was solubilized in DMSO at a
stock concentration of 1 mg/ml (1.6 mM), filter sterilized, and
split into 75 μl aliquots. SP600125 (Calbiochem, La Jolla, CA)
was solubilized in DMSO at a stock concentration of 10 mM,
filter sterilized and split into 75 μl aliquots. Puromycin (Sigma
Aldrich) was solubilized in water at a stock concentration of
2 mg/ml, filter sterilized and divided into 200 μl aliquots. A
stock solution of propidium iodide (PI) was created by
dissolving 5 mg of PI in 1 ml of PBS. All of the reagents
were protected from light and stored at −20 °C (PI was stored at
5 °C).
DNA primers and probes
Primers for RT-PCR and fluorescence-interference probes
for real-time PCR were ordered from Integrated DNA
technologies, Inc. (IDT, Coralville, IA). The primers were
utilized in PCR reactions at a final concentration of 400 nM.
Primers were designed as follows: CAEV Gagfor primer: 5′ATT
CTG TAA TGT TCC AGC AAC TGC 3′; CAEV Gagrev
primer: 5′ ATA TGC CAA CTG CCT TTC AAA GTC 3′;
Revfor primer: 5′ CTG ACG ATG GGA ATC TGG ATA AAT
GG 3′; Rrev primer: 5′ AGT GGATCC TGC GAG AGC CGC
TCT G 3′; 5′ U3rev primer: 5′ GGG AGATCTAGC TTG TTA
TTA GTC CTC TTTAGC CC 3′; TATA-bglfor primer: 5′ GGG
AGA TCT GCT GTA TAT AAG GGA GAA GCT TGC TGC
3′; AP4rev primer: 5′ GGG AGA TCT CAG CTG ATA TGT
CAG CTG TTA CAT CTG 3′; U3rev primer: 5′GGG AGATCT
CAT TTT GCT TTG TCA TAG TGA ACT TGC 3′; U3for
primer: 5′ GGG AGA TCT ATG CTT GCT CAT GCT GAC
ACT GTA GC 3′; AP4for primer: 5′ GGG AGATCT TGTAAC
AGC TGA CAT ATC AGC TGA TGC 3′; AMLrev primer: 5′
GGG AGA TCT GCA CTT GCG GTT ACA TTT TGC TTT
GTC 3′; β actin forward primer: 5′ CTC ACG GAG CAC GGC
TAT AG 3′; β actin reverse primer: 5′ GCA GAG CTT CTC
CTT GAT GTC A 3′; human matrix metalloproteinase 12
forward primer (MPfor): 5′ CTG GAC ACA TCT ACC CTG
GAG A 3′; MPrev primer: 5′ ACG GTT CAT GTC AGG TGT
GTA ATT 3′; 18s rRNAfor primer: 5′ GTA ACC CGT TGA
ACC CCATT 3′; 18s rRNArev primer: 5′ CCATCC AAT CGG
TAG TAG CG 3′.
The CAEV Gag and β actin fluorescence-interference
probes for real-time PCR were HPLC purified (IDT, Coralville,
IA) and utilized at a final concentration of 250 nM. The Gag
probe was designed as follows: 5′-/5HEX/AGC AAT GCA
GCA TGG CCT CGT GTC/BHQ-1/-3′ (where BHQ_1
represents Black Hole Quencher1). The β actin probe was
designed as follows: 5′-/FAM/TCA CCA CCA CTG CCG
AGC GGG AA/BHQ-1/-3′. The probes were protected from
light and stored at −20 °C.RNA isolation/RT-PCR assays
Total cellular RNA was purified utilizing one of the
following reagents or kits: Trizol Reagent (Invitrogen, Carls-
bad, CA), RNAeasy Mini Kit (Qiagen Inc., Valencia, CA) or
RiboPure Kit (Ambion, Austin, TX). The RNA was isolated
according to the protocols included with the kits and, if not
utilized immediately, was stored at −80 °C. DNase treatment
was accomplished with TURBO DNase (Ambion) utilizing
4 units DNase per 3 μg RNA and incubating the reaction for
30 min at 37 °C. The DNase was inactivated by incubating the
samples at 65 °C for 15 min. RNAwas reverse transcribed into
cDNA with the First Strand cDNA Synthesis Kit for RT-PCR
(Roche, Indianapolis, IN). Real-time PCR assays were
performed with TaqMan Universal Master Mix (Roche) or iQ
SYBR Green Supermix (Bio-Rad Laboratories, Hercules, CA)
on a Bio-Rad iCycler detection system. CAEV Gag or 18s
rRNA primer pairs were utilized for real-time PCR reactions;
each assay was performed in triplicate. A control sample was
run without reverse transcriptase to control for the DNase
treatment effectiveness. All experiments were controlled for
variations in the reverse transcriptase step and in the RNA
concentration by normalizing to either β actin or 18s rRNA
PCR products run in parallel with the same cDNA. The
normalization calculation was performed for each sample as
follows: [sample copy number/(sample actin or 18s copy
number/control actin or 18s copy number)]. When experiments
were performed with multiple cell lines, an integration constant
was generated by the following formula: genomic U937CAEV
gag copy number/cell line of interest genomic gag copy
number. This integration constant was then multiplied by the
value generated above to arrive at the final copy number
normalized by both the amount of 18s rRNA and the relative
number of integrated constructs within the cellular genome.
Standard PCR was performed with Platinum Taq DNA
polymerase (Invitrogen) on a GeneAmp PCR System 9600
(Perkin Elmer). PCR products from standard RT-PCR were run
on agarose gels, stained with ethidium bromide and digitally
photographed with a Multiimage Light Cabinet (Alpha Innotech
Corporation, San Leandro, CA) utilizing Alphaimager 2200
software. PCR product densitometry was performed with the
same software.
Genomic DNA isolation and PCR product sequencing
Genomic DNA was isolated from 5 × 105 cells utilizing a
Puregene genomic DNA isolation kit (Gentra Systems,
Minneapolis, MN). Standard PCR was performed with the
Revfor and Rrev primer set. Real-time PCR was performed with
CAEV Gag primers. The U3 LTR PCR product from U937CAEV
genomic DNAwas sequenced by Amplicon Express (Pullman,
WA).
Western blots and protein assays
3 × 106 U937CAEV cells were plated in 6-well plates, treated
with or without the Jun N-terminal kinase inhibitor SP600125,
198 B.G. Murphy et al. / Virology 352 (2006) 188–199incubated for 2 h at 37 °C, and subsequently treated with
cytokines or PMA. The plates were incubated for 4 additional
h at 37 °C, the cells were washed once with PBS and lysed
with 150 μl of lysis buffer (10 mM Tris pH 7.5, 100 mM
NaCl, 1 mM EDTA, 1% NP-40, 1% sodium dodecyl sulfate,
0.5% deoxycholate). The lysates were kept on ice, sheared by
pipetting through a 20-gauge needle and filtered through a
syringe-tip filter. If not used immediately, the lysates were
stored for up to 7 days at −20 °C. The cell lysates were
normalized for protein concentration utilizing a BCA Protein
Assay Kit (Pierce, Rockford, IL). The assays were run in
triplicate with at least two different sample dilutions. For each
assay, a nine sample standard curve was generated in duplicate
from the kit reagents. The sample absorption was determined
on a microplate reader (Titertek Multiskan MCC/340, EFLAB,
Finland) at a wavelength of 540 nm. The lysates were mixed
with loading buffer (0.03 M Tris (pH 6.8) containing 2% SDS,
10% glycerol, and 0.01% bromphenol blue in the presence of
100 mM dithiothreitol) (Ozyoruk et al., 2001), heated to 100
°C for 5 min and loaded onto a 4–20% gradient polyacryl-
amide gel (BioRad, Hercules, CA). The gel was run at 200 V
for 30 min and transblotted onto nitrocellulose at 100 V for
60 min. Western blotting was performed utilizing either rabbit
polyclonal IgG phospho-c-Jun (Ser 73) or rabbit monoclonal
IgG c-Jun (60A8) primary antibodies (PhosphoPlus c-Jun
Antibody Kit, Cell Signaling Technology, Beverly, MA)
according to the kit protocol.
Propidium iodide staining and flow cytometry
Propidium iodide (PI) staining was accomplished using a
modification of a published protocol (Villet et al., 2003).
Briefly, 2–3 × 106 U937CAEV cells were plated in 3-cm
diameter, 6-well plates with or without 40 μMSP600125. At the
appropriate time point, the cells were pelleted, washed once
with PBS, pelleted and resuspended in 1 ml PBS. 0.5 ml of 1%
paraformaldehyde was added, and the cells were incubated on
ice for 30 min. The cells were washed once with PBS,
resuspended in 0.5 ml PBS and treated with 90 μl of RNAse A
(10 mg/ml, 100 U/mg) for 30 min at room temperature. The
cells were washed again, resuspended in 1 ml PBS and treated
with 50 μl propidium iodide (1 mg/ml). The cells were stored in
the dark at 5 °C. A FACSort flow cytometer (Becton Dickinson,
San Jose, CA) equipped with Cell Quest software (Becton
Dickinson) was used to collect data. The data were analyzed and
figures generated with FlowJo software (Tree Star, Inc.,
Stanford University, Palo Alto, CA).
Statistics
The data are presented as the mean of three or more values
(bar) with the standard deviation displayed as error bars. A one
way analysis of variance (ANOVA) or Kruskal–Wallis one way
ANOVA was performed on each data set with three or more
parameters. Where global differences were identified, the
Student–Newman–Keuls (SNK) multiple comparison test was
used for select pair wise comparisons of the mean responsesbetween treatment groups. A P value of less than 0.05 was
considered to be statistically significant. All of the graphs were
generated in SigmaPlot and the statistics were performed with
SigmaStat software (Systat Software Inc. Richmond, CA).
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